Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review.

Department of Obstetrics & Gynaecology, University "Magna Graecia" of Catanzaro, Viale Europa, Catanzaro, Italy.
Gynecological Endocrinology (Impact Factor: 1.3). 02/2012; 28(9):710-21. DOI: 10.3109/09513590.2011.652247
Source: PubMed

ABSTRACT Nexplanon(®) is a new long-term reversible contraception method. The current review is aimed to analyze the published data concerning the contraceptive effectiveness of Nexplanon(®) and its effects on reproductive function. Pharmacological properties and technical procedures of insertion and removal, as well as the efficacy and safety data available, were discussed. Possible strategies for treating Nexplanon(®)-related bleeding were also described. With regard to the future research and the future scientific developments of contraceptive implants, the possible use of Nexplanon(®) wide-ranging for the symptomatic treatment of endometriosis and premenstrual syndrome (PMS) were considered. Finally, it was defined in which women the use of Nexplanon(®) is indicated and in which it is contra-indicated.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The original inserter of the contraceptive implant, Implanon®, resulted in very deep insertion in some cases, sometimes in close proximity to neurovascular structures. This occasionally resulted in removal complications. We successfully adopted a hook-wire marker method used in breast tumor surgery to safely and simply remove these deep-lying, non-palpable implants.
    Contraception 05/2013; · 3.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Desogestrel (DSG) is a third-generation progestin. It is commonly used in various formulations for hormonal contraception including combinations with ethinyl estradiol (EE), progestin-only pill and subdermal implants. DSG is also used in menopausal patients for hormone replacement therapy (HRT). Areas covered: The current manuscript aims to review the available data on safety and tolerability of DSG in oral contraception and HRT. The material included in the manuscript was searched and obtained via Medline, PubMed and EMBASE up to September 2012 using the search terms 'adverse events, side effects, tolerability' in combination with 'desogestrel and progestins'. Expert opinion: DSG is frequently used as contraceptive and it shows good contraceptive efficacy as demonstrated by the Pearl indexes reported in the studies reviewed in this manuscript. It is a versatile compound; in fact, it can be used either as progestin-only contraceptive or in combination with EE, and different formulations are available (such as the subdermal implant). In contraception, DSG is generally well tolerated but its use is associated with doubled risk of venous thromboembolism compared to second-generation progestins. Although DSG is efficacious in HRT, it may not represent the best choice due to the potential higher risk of breast cancer compared with progesterone or dydrogesterone.
    Expert Opinion on Drug Safety 04/2013; · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although short-acting reversible hormonal contraceptives, such as oral contraceptives and the contraceptive patch and vaginal ring, remain the most commonly used contraceptive methods in the United States, they are also associated with the highest failure rates. Long-acting reversible contraception (LARC) methods, such as intrauterine devices and contraceptive implants, offer high continuation rates and very low failure rates, and are safe for use in most women. The provision of LARC methods to adolescent, young adult and nulliparous women is a relatively new concept that offers an innovative option for these populations.
    Nursing for Women s Health 10/2013; 17(5):431-5.


Available from
May 20, 2014